Three generations of targeted therapies in chronic myeloid leukemia: Molecular advances, adverse effects, therapeutic challenges, and future perspectives
Modern CML management has transitioned from uniform kinase inhibition toward highly individualized survivorship, and Optimizing long-term quality of life relies on aligning tyrosine kinase inhibitor selection with patient-specific comorbidities, implementing response-adjusted dosing, and utilizing well-defined clinical...